Oncology Drug-Companion Diagnostic Combinations

Cancer Treatment and Research Communications ◽

10.1016/j.ctarc.2021.100492 ◽

2021 ◽

pp. 100492

Author(s):

Jan Trøst Jørgensen

Keyword(s):

Oncology Drug ◽

Companion Diagnostic

Download Full-text

FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

Case Medical Research ◽

10.31525/cmr-1a454b4 ◽

2019 ◽

Author(s):

Keyword(s):

Download Full-text

FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

Case Medical Research ◽

10.31525/fda2-ucm626710.htm ◽

2018 ◽

Author(s):

Keyword(s):

Download Full-text

A bivariate Bayesian framework for simultaneous evaluation of two candidate companion diagnostic assays in a new drug clinical trial

Biostatistics & Epidemiology ◽

10.1080/24709360.2021.1913705 ◽

2021 ◽

pp. 1-11

Author(s):

Richard M. Simon ◽

Songbai Wang

Keyword(s):

Clinical Trial ◽

Bayesian Framework ◽

Diagnostic Assays ◽

New Drug ◽

Simultaneous Evaluation ◽

Drug Clinical Trial ◽

Companion Diagnostic

Download Full-text

Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2

Thoracic Cancer ◽

10.1111/1759-7714.13797 ◽

2021 ◽

Vol 12 (6) ◽

pp. 906-913

Author(s):

Ken Uchibori ◽

Natsuki Takano ◽

Ryo Manabe ◽

Ryosuke Tsugitomi ◽

Shinsuke Ogusu ◽

...

Keyword(s):

Diagnostic Tests ◽

Companion Diagnostic

Download Full-text

Immunophenotyping, RNAseq, microbiota analysis of syngeneic mouse models treated with immune checkpoint inhibitors to support biomarker and immune-oncology drug discovery

European Journal of Cancer ◽

10.1016/s0959-8049(16)32919-7 ◽

2016 ◽

Vol 69 ◽

pp. S108

Author(s):

L. Zhang ◽

M. Qiao ◽

J. Zhang ◽

S. Guo ◽

W. Qian ◽

...

Keyword(s):

Drug Discovery ◽

Mouse Models ◽

Immune Checkpoint ◽

Immune Checkpoint Inhibitors ◽

Checkpoint Inhibitors ◽

Syngeneic Mouse ◽

Oncology Drug ◽

Microbiota Analysis ◽

Immune Oncology

Download Full-text

FDA Approval for Vectibix & Companion Diagnostic; Breakthrough Status for Elotuzumab & CO-1686

Oncology Times ◽

10.1097/01.cot.0000451730.95667.73 ◽

2014 ◽

Vol 36 (12) ◽

pp. 8

Author(s):

&NA;

Keyword(s):

Fda Approval ◽

Companion Diagnostic

Download Full-text

Next generation oncology drug development: opportunities and challenges

Nature Reviews Clinical Oncology ◽

10.1038/nrclinonc.2009.38 ◽

2009 ◽

Vol 6 (5) ◽

pp. 259-265 ◽

Author(s):

Martin E. Gutierrez ◽

Shivaani Kummar ◽

Giuseppe Giaccone

Keyword(s):

Drug Development ◽

Next Generation ◽

Oncology Drug ◽

Oncology Drug Development

Download Full-text

Website information on oncology drug benefits vs risks

Reactions Weekly ◽

10.1007/s40278-016-21377-5 ◽

2016 ◽

Vol 1620 (1) ◽

pp. 11-11

Keyword(s):

Drug Benefits ◽

Download Full-text

China's oncology drug market on the rise

The Lancet Oncology ◽

10.1016/s1470-2045(21)00176-5 ◽

2021 ◽

Vol 22 (5) ◽

pp. 586-587

Author(s):

Chris McCall

Keyword(s):

Drug Market ◽

Download Full-text

StatBite: FDA Oncology Drug Product Approvals in 2009

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/djq030 ◽

2010 ◽

Vol 102 (4) ◽

pp. 219-219 ◽

Keyword(s):

Drug Product ◽

Download Full-text